

doi: 10.13241/j.cnki.pmb.2021.04.017

先天性心脏病患儿术后并发医院感染的危险因素及其病原菌分布和药敏实验分析*

韩月英¹ 王厚照^{1△} 张雪梅² 林一¹ 尚碧莲¹

(1 中国人民解放军陆军第七十三集团军医院 / 厦门大学附属成功医院检验科 福建厦门 361004;

2 中国人民解放军陆军第七十三集团军医院 / 厦门大学附属成功医院儿科 福建厦门 361004)

摘要 目的:统计先天性心脏病(CHD)患儿术后医院感染的病原菌分布及细菌耐药性情况,分析影响CHD患儿术后医院感染的危险因素。**方法:**回顾性选取2010年3月-2017年10月我院行CHD手术治疗的患儿3800例,收集临床标本进行致病菌培养并进行药敏试验,统计CHD术后医院感染患儿病原菌种类及主要致病菌的耐药情况,分析影响CHD患儿术后医院感染的危险因素。**结果:**3800例CHD患儿术后医院感染率为3.13%(119/3800),共分离出菌株172株,G⁻菌、G⁺菌、真菌分别占55.81%(96/172)、26.74%(46/172)、17.44%(30/172)。肺炎克伯雷菌、大肠杆菌对头孢类抗生素高度耐药,鲍曼不动杆菌检出率逐年增高,且仅对多黏菌素B保持敏感;肺炎链球菌、凝固酶阴性葡萄球菌、金黄色葡萄球菌对大环内脂类抗生素、克林霉素、青霉素高度耐药,对万古霉素和替加环素保持敏感。术后医院感染与年龄、体重、病程、手术时间、体外循环时间、机械通气时间、ICU停留时间、住院时间、合并肺动脉高压、吸痰次数、静脉营养、应用丙种球蛋白或白蛋白有关($P<0.05$),且合并肺动脉高压、体外循环时间≥100 min、机械通气时间≥120 h、吸痰次数≥5次/d是CHD患儿术后医院感染的危险因素($P<0.05$)。**结论:**G⁻菌、G⁺菌是CHD患儿术后医院感染的主要致病菌,且对常用抗生素高度耐药,此外鲍曼不动杆菌的检出率和耐药性上升极为明显,合并肺动脉高压、体外循环时间及机械通气时间过长、吸痰次数多的CHD患儿医院感染风险升高。

关键词:先天性心脏病;医院感染;危险因素;病原菌;药敏试验

中图分类号:R541.1 文献标识码:A 文章编号:1673-6273(2021)04-683-05

Risk Factors of Postoperative Nosocomial Infection in Children with Congenital Heart Disease and Their Pathogenic Bacteria Distribution and Drug Sensitivity Analysis*

HAN Yue-ying¹, WANG Hou-zhao^{1△}, ZHANG Xue-mei², LIN Yi¹, SHANG Bi-lian¹

(1 Department of Clinical Laboratory, The 73rd Army Hospital of Chinese People's Liberation Army/Xiamen University Affiliated Chenggong Hospital, Xiamen, Fujian, 361004, China; 2 Department of Pediatrics, The 73rd Army Hospital of Chinese People's Liberation Army/Xiamen University Affiliated Chenggong Hospital, Xiamen, Fujian, 361004, China)

ABSTRACT Objective: To investigate the distribution of pathogens and bacterial resistance of postoperative nosocomial infection in children with congenital heart disease (CHD), and analyze the risk factors of postoperative nosocomial infection in children with CHD. **Methods:** 3800 cases of CHD children after surgical treatment in our hospital from March 2010 to October 2017 were selected retrospectively. Clinical specimens were collected for pathogen culture and drug sensitivity test, the types of pathogens and the drug resistance of main pathogens were analyzed, the risk factors of postoperative nosocomial infection in children with CHD were analyzed. **Results:** The hospital infection rate of 3800 children with CHD was 3.13% (119/3800), A total of 172 strains were isolated, G⁻ strain, G⁺ strain and fungi accounted for 55.81% (96/172), 26.74% (46/172) and 17.44% (30/172) respectively. Klebsiella pneumoniae and Escherichia coli have high resistance rate to cephalosporins, the detection rate of Acinetobacter baumannii is increasing year by year, and it was sensitive to polymyxin B only; Streptococcus pneumoniae, coagulase negative Staphylococcus and Staphylococcus aureus are highly resistant to lipid antibiotics, clindamycin and penicillin, and sensitive to vancomycin and tegacycline. The postoperative hospital infection were related to age, weight, course of disease, time of operation, time of cardiopulmonary bypass, mechanical ventilation time, ICU stay time, length of stay, whether pulmonary hypertension, phlegm times, intravenous nutrition, use of gamma globulin or white protein ($P<0.05$), and pulmonary hypertension, cardiopulmonary bypass time greater than or equal to 100 min, mechanical ventilation time greater than or equal to 120 h, sputum number greater than or equal to 5 times/d were risk factors for postoperative hospital infection in children with CHD ($P<0.05$).

* 基金项目:福建省自然科学基金面上项目(2018D0017)

作者简介:韩月英(1985-),女,本科,初级检验技师,研究方向:临床检验,E-mail: moonhan85@163.com

△ 通讯作者:王厚照(1970-),男,硕士,副主任技师,研究方向:检验医学,E-mail: wanghouzhao121@163.com

(收稿日期:2020-04-30 接受日期:2020-05-26)

Conclusion: G⁻ strain, G⁺ strain are the main pathogenic bacteria of postoperative hospital infection in children with CHD, and highly resistant to common antibiotics, in addition, the detection rate and drug resistance of *Acinetobacter baumannii* increased significantly, the risk of infection in children with pulmonary hypertension, cardiopulmonary bypass and mechanical ventilation time too long, too many sputum number is increased.

Key words: Congenital heart disease; Nosocomial infection; Risk factors; Distribution of pathogens; Drug sensitivity analysis

Chinese Library Classification(CLC): R541.1 Document code: A

Article ID: 1673-6273(2021)04-683-05

前言

先天性心脏病(Congenital heart disease, CHD)患儿由于年龄偏小,机体抵抗力较弱,各器官、组织功能发育迟缓,术后易出现感染,感染率高达5%-21%^[1,2]。CHD患儿经历术中体外循环、术后机械通气和频繁侵入性操作,加之营养状态较差等多种因素影响,医院感染率有升高趋势,易感病原菌常累及呼吸系统、血液系统,严重感染可导致脓毒血症和多器官功能衰竭,延长患儿住院时间,且长时间的抗生素滥用导致病菌易出现耐药性,均可导致患儿死亡^[3-5]。由于病原菌分布及耐药特征因时间、地区的差异性,相关报道关于医院感染的病原菌分布和耐药情况不尽相同^[6,7],为了解我院CHD患儿术后医院感染的常见病原菌特征、耐药性以及导致感染的因素,为临床防治感染以及合理使用抗生素提供参考,本研究拟对我院3800例CHD患儿进行回顾性分析,现报道如下。

1 资料与方法

1.1 一般资料

回顾性选取2010年3月至2017年10月我院行CHD手术治疗的3800例患儿,收集其临床资料。纳入标准:(1)经临床确诊为CHD^[8]患儿;(2)符合CHD手术指征;(3)均成功完成了CHD手术。排除标准:(1)川崎病、风湿等后天因素所致心脏病患儿;(2)术前即发现病菌感染的患儿。依据术后医院感染的诊断标准将患儿分为感染组和未感染组,感染判定:有感染的症状体征或影像学阳性以及微生物学证据的感染,血或其他送检标本培养阳性,并伴有相应的临床感染证据^[9]。

1.2 病原菌培养和药敏实验方法

采集血液、痰液、分泌物、尿液、灌洗液或咽拭子等标本进行细菌培养和药敏试验。培养方法:对收集的标本进行涂片观察后选取合格标本(鳞状上皮细胞<10个HP)培养24 h,采用法国生物-梅里埃ATB系列微生物检验仪和配套细菌鉴定试条进行致病菌鉴定,操作流程严格遵守美国临床实验室标准化研究所(CLSI)颁布的标准^[10]。药敏试验主要采取MIC法或K-B法,取纯菌落标本,应用法国梅里埃ATB系列自动药敏鉴定分析仪进行药敏试验。

1.3 统计学分析

采用SPSS22.0软件进行数据分析,计量资料以($\bar{x} \pm s$)表示,实施t检验,计数资料以%表示,采用 χ^2 检验,单因素和多因素Logistic回归分析CHD患儿术后医院感染的危险因素,设置检验水准 $\alpha=0.05$ 。

2 结果

2.1 CHD患儿医院感染情况和致病菌谱

3800例患儿术后医院感染119例,无感染3681例;共分离出菌株172株,其中G⁺菌株46株,占26.74%(46/172),G⁻菌株96株,占55.81%(96/172),真菌菌株30株,占17.44%(30/172)。G⁻菌以肺炎克雷伯菌(28.13%)检出率最高,G⁺菌以凝固酶阴性葡萄球菌(26.09%)检出率最高,真菌以白假丝酵母菌(36.67%)检出率最高。见表1。

表1 CHD患儿术后医院感染病原菌分布

Table 1 Distribution of pathogenic bacteria in children with CHD after surgery

Pathogenic bacteria	Number of bacteria[n(%)]
G ⁻	
<i>Klebsiella pneumoniae</i>	27(28.13)
<i>Escherichia coli</i>	21(21.88)
<i>Acinetobacter baumannii</i>	19(19.79)
<i>Pseudomonas aeruginosa</i>	16(16.67)
<i>Stenotrophomonas maltophilia</i>	7(7.29)
<i>Klebsiella oxytoca</i>	4(4.17)
<i>Acinetobacter lwoffii</i>	2(2.08)
G ⁺	
<i>Coagulase negative Staphylococcus</i>	12(26.09)
<i>Staphylococcus aureus</i>	10(21.74)
<i>Streptococcus pneumoniae</i>	9(19.57)
<i>Pyogenic cocci</i>	7(15.22)
<i>Enterococcus faecalis</i>	5(10.87)
<i>Staphylococcus haemolyticus</i>	3(6.52)
Fungus	
<i>Candida albicans</i>	11(36.67)
<i>Aspergillus</i>	9(30.00)
<i>Aspergillus niger</i>	6(20.00)
<i>Candida near smooth</i>	4(13.33)

2.2 主要致病菌的药敏鉴定结果

2010年3月-2013年3月(T1)、2013年4月-2016年3月(T2)、2016年4月-2017年10月(T3)期间检出主要细菌菌株数(G⁻菌和G⁺菌)分别为36株、49株、57株,鲍曼不动杆菌在细菌菌株的检出率分别为8.33%、10.20%、19.30%,呈明显增

长趋势。肺炎克伯雷菌、大肠杆菌对头孢类抗生素有较高的耐药率,且耐药率逐渐上升,对亚胺培南、哌拉西林/他唑巴坦保持较低的耐药率;鲍曼不动杆菌对头孢类和亚胺培南、碳青霉烯类抗生素均有较高的耐药率,但对多黏菌素B保持敏感;铜

绿假单胞菌对亚胺培南、左旋氧氟沙星的耐药率较高,且耐药率有上升趋势。肺炎链球菌、凝固酶阴性葡萄球菌、金黄色葡萄球菌对大环内脂类抗生素、克林霉素、青霉素均高度耐药,对万古霉素和替加环素完全不耐药,见表2、3。

表2 G⁻菌株药物耐药情况[例(%)]
Table 2 Drug resistance of G⁻ strains [n(%)]

Antibiotics	<i>Klebsiella pneumoniae</i>			<i>Escherichia coli</i>			<i>Acinetobacter baumannii</i>		
	T1(n=9)	T2(n=8)	T3(n=10)	T1(n=5)	T2(n=7)	T3(n=9)	T1(n=3)	T2(n=5)	T3(n=11)
Imipenem	2(22.22)	1(12.50)	3(30.00)	0(0.00)	1(14.29)	0(0.00)	2(66.67)	3(60.00)	10(90.91)
Piperacillin / tazobactam	1(11.11)	2(25.00)	0(0.00)	0(0.00)	1(14.29)	0(0.00)	2(66.67)	4(80.00)	10(90.91)
Cefepime	1(11.11)	4(50.00)	6(60.00)	3(60.00)	5(71.43)	7(77.78)	1(33.33)	3(60.00)	9(81.82)
Amikacin	1(11.11)	2(25.00)	1(10.00)	2(40.00)	3(42.86)	5(55.56)	/	/	/
Levofloxacin	/	/	/	/	/	/	1(33.33)	3(60.00)	8(72.73)
Ceftazidime	4(44.44)	4(50.00)	6(60.00)	2(40.00)	3(42.86)	5(55.56)	1(33.33)	2(40.00)	6(54.55)
Amoxicillin	3(33.33)	2(25.00)	4(40.00)	0(0.00)	2(28.57)	4(44.44)	/	/	/
Cefoperazone / sulbactam	3(33.33)	4(50.00)	3(30.00)	1(20.00)	2(28.57)	2(22.22)	/	/	/
Compound Xinnuoming	3(33.33)	5(62.50)	7(70.00)	2(40.00)	3(42.86)	5(55.56)	1(33.33)	3(60.00)	7(63.64)
Cefotaxime	5(55.56)	6(75.00)	8(80.00)	3(60.00)	5(71.43)	7(77.78)	2(66.67)	4(80.00)	10(90.91)
Ceftriaxone	4(44.44)	5(62.50)	9(90.00)	4(80.00)	6(85.71)	8(88.89)	1(33.33)	5(100.00)	11(100.00)
polymyxin B	0(0.00)	0(0.00)	0(0.00)	/	/	/	0(0.00)	0(0.00)	0(0.00)

Notes: "/" shows undetected items.

表3 G⁺菌株药物耐药率[例(%)]
Table 3 Drug resistance of G⁺ strains [n(%)]

Antibiotics	<i>Streptococcus pneumoniae</i>			<i>Coagulase negative Staphylococcus</i>			<i>Staphylococcus aureus</i>		
	T1(n=2)	T2(n=5)	T3(n=2)	T1(n=2)	T2(n=3)	T3(n=7)	T1(n=5)	T2(n=3)	T3(n=2)
Clindamycin	1(50.00)	4(80.00)	2(100.00)	1(50.00)	1(33.33)	2(28.57)	5(100.00)	2(66.67)	2(100.00)
Gentamicin	/	/	/	0(0.00)	1(33.33)	1(14.29)	1(20.00)	0(0.00)	0(0.00)
Erythromycin	1(50.00)	4(80.00)	2(100.00)	2(100.00)	2(66.67)	7(100.00)	4(80.00)	3(100.00)	2(100.00)
Penicillin	2(100.00)	5(100.00)	2(100.00)	2(100.00)	3(100.00)	7(100.00)	/	/	/
Levofloxacin	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	1(33.33)	0(0.00)
Compound Xinnuoming	1(50.00)	2(40.00)	1(50.00)	1(50.00)	0(0.00)	3(42.86)	2(40.00)	1(33.33)	1(50.00)
Tetracycline	1(50.00)	3(60.00)	1(50.00)	2(100.00)	3(100.00)	7(100.00)	/	/	/
Vancomycin	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	/	/	/
Tegafyline	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
Ciprofloxacin	0(0.00)	1(20.00)	1(50.00)	/	/	/	0(0.00)	0(0.00)	1(50.00)
Meropenem	/	/	/	1(50.00)	1(33.33)	1(14.29)	/	/	/

Notes: "/" shows undetected items.

2.3 CHD 术后感染的单因素分析

与未感染组相比,感染组患儿年龄偏小、体重偏轻($P < 0.05$),病程、手术时间、体外循环时间、机械通气时间、ICU 停

留时间、住院时间均长于未感染组患儿($P < 0.05$),合并肺动脉高压、吸痰次数≥5 次/d、静脉营养、应用丙种球蛋白或白蛋白的患儿比例明显高于未感染组($P < 0.05$),见表4。

表 4 感染患儿和未感染患儿临床基线资料对比

Table 4 Clinical baseline data comparison with infected and uninfected children

Factors	Infection group(n=119)	Uninfected group(n=3681)	t/x ²	P
Gender[n(%)]				
Male	62(52.10)	1871(50.83)	0.075	0.785
Female	57(47.90)	1810(49.17)		
Age(years)	1.81± 0.93	3.52± 2.09	8.896	0.000
Weights(kg)	8.05± 3.21	12.54± 5.33	9.135	0.000
Course of disease(years)	1.22± 0.39	0.84± 0.13	28.087	0.000
Pulmonary hypertension[n(%)]				
Yes	49(41.18)	801(21.76)	25.025	0.000
No	70(58.82)	2880(78.24)		
Operative time(min)	329.51± 171.05	183.66± 82.41	18.095	0.000
cardiopulmonary bypass time(min)	106.41± 53.70	50.32± 18.66	29.144	0.000
mechanical ventilation time(h)	163.05± 92.17	21.62± 9.11	81.828	0.000
ICU stay time(h)	368.25± 105.44	51.32± 26.42	106.45	0.000
Length of stay(d)	25.03± 10.95	17.05± 3.19	23.245	0.000
Use of intravenous nutrition support [n(%)]	26(21.85)	357(9.70)	18.777	0.000
sputum number greater than or equal to 5 times/d [n(%)]	37(31.09)	499 (13.56)	29.259	0.000
use of gamma globulin or white protein[n(%)]	42(35.29)	231(6.28)	35.065	0.000

2.4 先天性心脏病患儿术后医院感染的 Logistic 非条件回归分析

以 CHD 患儿术后是否发生医院感染为因变量, 以表 4 中有统计学意义的项目为自变量, 建立 Logistic 回归分析模型,

结果显示合并肺动脉高压、体外循环时间≥ 100 min、机械通气时间≥ 120 h、吸痰次数≥ 5 次 /d 是 CHD 患儿术后感染的危险因素($P<0.05$), 见表 5。

表 5 CHD 患儿术后医院感染的多因素分析结果

Table 5 Multi-factor analysis results of postoperative infection of children with CHD

Factors	β	SE	Wald x^2	P	OR	95%CI
Pulmonary hypertension	0.526	0.026	6.035	0.002	2.311	1.981-2.564
cardiopulmonary bypass time greater than or equal to 100 min	0.356	0.048	21.562	0.000	5.621	4.264-6.619
mechanical ventilation time greater than or equal to 120 h	0.369	0.037	10.255	0.001	4.862	3.336-5.769
sputum number greater than or equal to 5 times/d	0.723	0.041	29.034	0.000	5.261	4.264-5.961

3 讨论

本研究显示 G⁻ 菌、G⁺ 菌是我院 CHD 患儿术后医院感染的主要致病菌, 这与既往研究中发现术后医院感染的致病菌分布情况相一致^[10-12]。G⁻ 菌以肺炎克雷伯菌检出率最高, 其次为大肠埃希菌、鲍曼不动杆菌、铜绿假单胞菌, 且自 2010 年至 2017 年肺炎克雷伯菌、大肠埃希菌、铜绿假单胞菌一直稳定保持着较高的检出率, 说明非发酵菌已经成为我院院内感染的主要病

原菌, 这是因为非发酵菌为条件致病菌, 可通过多种传播途径引起呼吸道感染、泌尿道感染、皮肤感染, 而在医院中环境相对封闭, 且各类病人较多, 因此肺炎克雷伯菌、大肠埃希菌是医院感染的主要致病菌^[13-15]。徐红亮^[16]等人分析了 112 株来自下呼吸道感染的 CHD 患儿痰液标本, 发现 G⁻ 菌以肺炎克雷伯菌、鲍曼不动杆菌、铜绿假单胞菌居多, 与本研究结果基本一致, 不同的是大肠埃希菌构成比较低仅 6.2%, 与本研究存在一定的差异, 可能与病原菌地区差异性有关。

药敏试验显示肺炎克伯雷菌、大肠杆菌对头孢类抗生素有较高的耐药率,且耐药程度逐年上升,且存在多重耐药,可能与临床广泛使用头孢类抗生素有关^[17,18]。位居第三位的鲍曼不动杆菌检出率逐年提高,由 8.83%增加到 19.30%,且对头孢类、亚胺培南、碳青霉烯类等抗生素产生高度耐药,且耐药率逐渐提高。鲍曼不动杆菌是一种广泛存在于自然界和医院环境中的条件致病菌,除多黏菌素 B 外几乎对常规抗菌药物全部耐药,引起医药和微生物学界的关注,被称为“超级细菌”^[19-21],虽然多黏菌素 B 不良反应大,不宜作为小儿抗感染首选药物,但当 CHD 术后感染鲍曼不动杆菌时,宜考虑使用多黏菌素 B 进行抗感染治疗,同时本研究结果显示 G⁺ 菌对大环内脂类抗生素、克林霉素、青霉素均有高度耐药性,而对万古霉素和替加环素的耐药性普遍较低,提示万古霉素和替加环素可作为抗 G⁺ 菌感染的有效手段。

本研究还分析了 CHD 患儿术后医院感染的危险因素因素,结果显示肺动脉高压、体外循环时间≥ 100 min、机械通气时间≥ 120h、吸痰次数≥ 5 次 /d 是 CHD 患儿术后感染的危险因素,这是因为肺动脉高压是 CHD 常见的合并症,也是 CHD 患儿围术期死亡的主要原因,由于肺动脉高压患儿心肌受累严重,对手术耐受性差,术后发生感染的危险性高^[22,23]。体外循环可能始动全身炎症反应综合征,引发炎症介质释放,术后易发生的呼吸机相关性肺炎、脓毒症,甚至多器官功能衰竭等^[24,25]。张建国^[26]研究结果显示,CHD 患儿术后合并呼吸道感染与体外循环时间显著相关。机械通气患者免疫力低下,为条件致病菌侵袭提供了条件,丁艳苓^[27]等人研究显示持续机械通气时间不仅增加呼吸机相关肺炎的感染机率,同时对下呼吸道病原菌分布产生影响,z 这可能与机械通气患者下呼吸道病原菌特点及上机前和维持机械通气期间的经验治疗等有关。机械通气时间越长,下呼吸道开放时间越长、直接接触病原菌的机会越多,预防性使用抗生素量越大,耐药性越重,感染越重,同时机械通气时间的延长促使气管内壁形成细菌生物膜,减弱抗菌药物对细菌杀伤作用导致耐药形成^[28-30]。

综上,合并肺动脉高压、术后体外循环时间过长、机械通气时间过长、频繁吸痰的 CHD 患儿术后感染风险较高,且主要致病菌 G⁻ 菌、G⁺ 菌均存在明显的耐药现象,其中鲍曼不动杆菌的耐药性极为突出,临床需合理选择抗生素,提高患儿机体免疫力,严格无菌操作,减少不必要的侵入性操作以降低 CHD 患儿术后医院感染的几率。

参考文献(References)

- [1] Thomford NE, Dzobo K, Yao NA, et al. Genomics and Epigenomics of Congenital Heart Defects: Expert Review and Lessons Learned in Africa[J]. OMICS, 2018, 22(5): 301-321
- [2] 张清秀, 郭琰, 甄景慧, 等. 重症监护室术后先天性心脏病患儿院内感染病原菌特征及耐药分析 [J]. 职业与健康, 2017, 33(18): 2478-2482
- [3] 李雅莉, 张波, 黄建玲, 等. 腹膜透析治疗对先天性心脏病患儿术后血清因子水平及预后的影响 [J]. 现代生物医学进展, 2018, 18(18): 3514-3517
- [4] IHaponiuk I, Jaworski R, Paczkowski K, et al. Postoperative kinetics of common inflammatory biomarkers in postoperative course after congenital heart defects procedures with extracorporeal circulation in children[J]. Kardiol Pol, 2018, 76(6): 968-973
- [5] Vo D, Zurakowski D, Faraoni D. Incidence and predictors of 30-day postoperative readmission in children [J]. Paediatr Anaesth, 2018, 28(1): 63-70
- [6] 彭静, 张勇, 龙元, 等. 左向右分流型先天性心脏病合并下呼吸道感染患儿痰培养病原菌特点及耐药性分析 [J]. 儿科药学杂志, 2018, 24(2): 46-49
- [7] 徐红亮, 杨玉齐, 范顺阳, 等. 先天性心脏病患儿术后下呼吸道感染病原菌分布与耐药性分析 [J]. 中华医院感染学杂志, 2016, 26(1): 182-184
- [8] 梁峰, 沈珠军, 方全, 等. 2015 年欧洲心脏病学会关于心肌病、遗传性心律失常、小儿和先天性心脏病患者室性心律失常治疗和心脏猝死预防指南解读 [J]. 中国心血管杂志, 2016, 21(5): 413-418
- [9] 中华人民共和国卫生部. 医院感染诊断标准(试行)[J]. 现代实用医学, 2003, 15(7): 460-465
- [10] Fernández-Ugidos P, Barge-Caballero E, Gómez-López R, et al. In-hospital postoperative infection after heart transplantation: Risk factors and development of a novel predictive score[J]. Transpl Infect Dis, 2019, 21(4): e13104
- [11] García-Arribas D, Vilacosta I, Ortega Candal A, et al. Usefulness of positron emission tomography/computed tomography in patients with valve-tube graft infection[J]. Heart, 2018, 104(17): 1447-1454
- [12] 阳爱梅, 郭予雄, 侯铁英, 等. 儿科重症监护病房先天性心脏病术后肺炎克雷伯杆菌感染临床特点及药敏分析 [J]. 岭南心血管病杂志, 2017, 23(6): 718-721
- [13] Yu X, Chen M, Liu X, et al. Risk factors of nosocomial infection after cardiac surgery in children with congenital heart disease [J]. BMC Infect Dis, 2020, 21(1): 64
- [14] 刘建民, 刘建斌, 叶蕾, 等. 先天性心脏病和心脏瓣膜病术后肺部感染的相关因素分析 [J]. 安徽医药, 2019, 23(4): 707-709
- [15] Bhatt PJ, Ali M, Rana M, et al. Infections due to multidrug-resistant organisms following heart transplantation: Epidemiology, microbiology, and outcomes[J]. Transpl Infect Dis, 2020, 22(1): e13215
- [16] 徐红亮, 杨玉齐, 范顺阳, 等. 先天性心脏病患儿术后下呼吸道感染病原菌分布与耐药性分析 [J]. 中华医院感染学杂志, 2016, 26(1): 182-184
- [17] Collignon PJ, McEwen SA. One Health-Its Importance in Helping to Better Control Antimicrobial Resistance [J]. Trop Med Infect Dis, 2019, 4(1): E22
- [18] Abilova V, Kurdi A, Godman B. Ongoing initiatives in Azerbaijan to improve the use of antibiotics; findings and implications [J]. Expert Rev Anti Infect Ther, 2018, 16(1): 77-84
- [19] Mirnejad R, Heidary M, Bahramian A, et al. Evaluation of Polymyxin B Susceptibility Profile and Detection of Drug Resistance Genes among Acinetobacter baumannii Clinical Isolates in Tehran, Iran during 2015-2016 [J]. Mediterr J Hematol Infect Dis, 2018, 10 (1): e2018044
- [20] Laudy AE. Non-antibiotics, Efflux Pumps and Drug Resistance of Gram-negative Rods[J]. Pol J Microbiol, 2018, 67(2): 129-135
- [21] Wieland K, Chhatwal P, Vonberg RP. Nosocomial outbreaks caused by Acinetobacter baumannii and Pseudomonas aeruginosa: Results of a systematic review[J]. Am J Infect Control, 2018, 46(6): 643-648

(下转第 682 页)

- [17] Vanessa Taieb, Hidetoshi Ikeoka, Fang-Fang Ma, et al. A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients [J]. Current Medical Research and Opinion, 2019, 35(2): 1-1
- [18] Tianlin Guo, Rachel Heon-Roberts, Chunxia Zou, et al. Selective Inhibitors of Human Neuraminidase 1 (NEU1)[J]. Journal of Medicinal Chemistry, 2018, 61(24): 111-112
- [19] Root CF, Fine JS, Clayson KJ. Isoelectric focusing of neuraminidase-treated alkaline phosphatase isoenzymes on agarose gel [J]. Clinical Chemistry, 2020, 41(6): e6
- [20] Tewawong N, Marathe B M, Yong P. Neuraminidase inhibitor susceptibility and neuraminidase enzyme kinetics of human influenza A and B viruses circulating in Thailand in 2010-2015 [J]. PLoS One, 2018, 13(1): e0190877
- [21] Ling Wang, Xiaobin Fang, Yongling Yang, et al. Design and application of bundle treatment plan in the early stage for severe human infection by avian influenza H7N9[J]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, 2018, 30(1): 24-28
- [22] Chao Hu, Jing Zheng, Jia Miao, et al. Pharmacokinetics of Phosphate Retaglitin Tablet in Patients with Renal Dysfunction[J]. Journal of Sichuan University. Medical science edition, 2018, 49(1): 74-80
- [23] Nozomu Yoshino, Ai Kawamura, Akira Ishii, et al. Vogt-Koyanagi-Harada Disease Associated with Influenza A Virus Infection: A Case Report[J]. Intern Med, 2018, 57(11): 1661-1665
- [24] Pnq P, Mostafa HH, Marathe BM, et al. Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection[J]. Sci Rep, 2017, 7(1): e7345
- [25] Lee Jonghoo, Park Ju-Hee, Jwa Hyeyoung, et al. Comparison of Efficacy of Intravenous Peramivir and Oral Oseltamivir for the Treatment of Influenza: Systematic Review and Meta-Analysis[J]. Yonsei Medical Journal, 2017, 58(4): 778-785
- [26] Nakamura Y, Sugawara T, Ohkusa Y, et al. Severe abnormal behavior incidence after administration of neuraminidase inhibitors using the national database of medical claims[J]. J Infect Chemother, 2018, 24(3): 177-181
- [27] Vanchiere, John, Plunkett, Stephanie, Annamalai, Rajasekaran, et al. Single Dose IV Peramivir is Safe and Effective in the Treatment of Pediatric Influenza[J]. Open Forum Infectious Diseases, 2017, 4(suppl_1): S694-S694
- [28] Gubareva, Larisa V, Sleeman, Katrina, Guo, Zhu, et al. Drug Susceptibility Evaluation of an Influenza A (H7N9) Virus by Analyzing Recombinant Neuraminidase Proteins[J]. Journal of Infectious Diseases, 2017, 216(4): S566-S574
- [29] Lackenby Angie, Besselaar Terry G, Daniels Rod S, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017 [J]. Antiviral Research, 2018, 24(6): 449-457
- [30] Nakamura, Shigeki, Miyazaki, Taiga, Izumikawa, Koichi, et al. Efficacy and Safety of Intravenous Peramivir Compared With Oseltamivir in High-Risk Patients Infected With Influenza A and B Viruses: A Multicenter Randomized Controlled Study[J]. Open Forum Infect Dis, 2017, 4(3): e129

(上接第 687 页)

- [22] Varela DL, Teleb M, Elmallah W. Advanced therapies for the management of adults with pulmonary arterial hypertension due to congenital heart disease: a systematic review [J]. Open Heart, 2018, 5(1): e000744
- [23] Kayali S, Ertugrul I, Yoldas T, et al. Sensitive Cardiac Troponins: Could They Be New Biomarkers in Pediatric Pulmonary Hypertension Due to Congenital Heart Disease? [J]. Pediatr Cardiol, 2018, 39(4): 1-8
- [24] 何勇, 李中杰, 刘光强, 等. 体外循环和非体外循环冠状动脉旁路移植术对肾功能不全患者肾脏功能的损伤比较[J]. 中国临床研究, 2019, 32(9): 1185-1188
- [25] Paruk F, Sime FB, Lipman J, et al. Dosing antibiotic prophylaxis during cardiopulmonary bypass-a higher level of complexity? A structured review[J]. Int J Antimicrob Agents, 2017, 49(4): 395-402
- [26] 张建国. 小儿先天性心脏病合并下呼吸道感染的因素分析及预防对策[J]. 中西医结合心血管病电子杂志, 2015, 3(36): 59-60
- [27] 潘丽娟, 王荣丽. 呼吸机相关性肺炎病原菌的分布及危险因素分析[J]. 中国感染与化疗杂志, 2019, 19(4): 363-365
- [28] 宋春梅, 康瑞, 巩若箴, 等. 左向右分流型先天性心脏病患儿肺部病变的特点分析[J]. 医学影像学杂志, 2016, 26(12): 2216-2220
- [29] Gade AR, Patel M, West DR, et al. Prevalence of HCV Infection in Adults with Congenital Heart Disease and Treatment with Direct Antiviral Agents[J]. South Med J, 2018, 111(3): 137-141
- [30] 黄淑群, 岑浩锋, 孙优异, 等. 抗生素联合外科手术及心理干预治疗先天性心脏病合并感染性心内膜炎的效果分析[J]. 中国生化药物杂志, 2017, 37(5): 435-437